A bioassay for possible carcinogenicity of @entity2515 , an antihypertensive drug for @entity1 use, was conducted by administering the test chemical in feed to F344 @entity35 and B6C3F1 @entity19 . Groups of 50 @entity35 and 50 @entity19 of each sex were administered @entity2515 at two doses, 5 ppm and 10 ppm, for 103 weeks and then observed for an additional 2 weeks. Matched controls consisted of groups of 50 untreated @entity35 and 50 untreated @entity19 of each sex. All surviving animals were killed and necropsied at the end of 104 or 105 weeks. The significant effects that could be related to administration of @entity2515 at the doses used were decreased body weight and increased @entity5 formation in dosed male @entity35 and in @entity19 of both sexes. Dosed male @entity35 had an increased incidence of adrenal medullary pheochromocytomas. Among dosed @entity19 , some males developed @entity15023 , which rarely occur in control @entity19 , and females had an increased incidence of mammary @entity5 . It was concluded that, under the conditions of the bioassay, @entity2515 was carcinogenic in male @entity35 and in @entity19 of both sexes, producing three different kinds of @entity5 . @entity2515 was not carcinogenic for female @entity35 , but they may not have received a high enough dose for maximum test sensitivity. Levels of Evidence of Carcinogenicity: Male @entity35 : Positive Female @entity35 : Negative Male @entity19 : Positive Female @entity19 : Positive

Bioassay of XXXX for Possible Carcinogenicity (CAS No. 50-55-5).

@entity1 :: ('9606', 'Species') :: ['human'] @entity2515 :: ('MESH:D012110', 'Chemical') :: ['reserpine'] @entity19 :: ('10090', 'Species') :: ['mice', 'Mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer'] @entity15023 :: ('MESH:C537244', 'Disease') :: ['undifferentiatedcarcinomas of the seminal vesicles'] @entity35 :: ('10116', 'Species') :: ['Rats', 'rats']
@entity2515 :: (MESH:D012110,Chemical) :: ['Reserpine']
